Roth Capital Initiates Celladon At Buy

Analysts at Roth Capital initiated coverage on Celladon Corporation CLDN with a Buy rating. Celladon shares have gained 70.15% over the past 52 weeks, while the S&P 500 index has surged 11.80% in the same period. Celladon's shares rose 10.69% to $21.75 in pre-market trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: InitiationAnalyst RatingsRoth Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!